Clinical study of an oral contraceptive in single monthly dose: quinestrol - quingestanol

Authors

  • Boris Rubio L. Profesor Titular de Ginecología y Obstetricia, Facultad de Medicina, Universidad Nacional Autónoma de Mexico, D.F., Mexico
  • Ramón González A. Jefe del Servicio de Ginecología, Hospital de la Villa, D.F., Mexico

DOI:

https://doi.org/10.31403/rpgo.v15i823

Abstract

The author has studied the contraceptive effect of 2 mg. of quinestrol administered the 2nd day and 22 day of the cycle plus 2.5 mg. of quingestanol acetate in the 22 day: 256 women with a total of 2610 cycles were studied; none of the women became pregnant during the treatment. The side effects registered nausea, vomiting, cephalea and mastalgia as well as mucorrhea; in most of the patients these symptoms had dissapeared of the 5th cycle of treatment intermenstrual spotting was observed in the first three months with an incidence of 25% and 24.6% then diminished to 4,9 and 3%. The laboratory data did not show modifications in these women.

Downloads

Download data is not yet available.

Published

2015-06-10

How to Cite

Rubio L., B., & González A., R. (2015). Clinical study of an oral contraceptive in single monthly dose: quinestrol - quingestanol. The Peruvian Journal of Gynecology and Obstetrics, 15(2), 151–158. https://doi.org/10.31403/rpgo.v15i823

Issue

Section

Artículos Originales